The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy

Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01106274

Acronym

C3R

Enrollment

Registered

2010-04-19

Start date

2008-11-30

Completion date

2009-09-30

Last updated

2010-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous Keratopathy

Brief summary

Recently, riboflavin (0.1%) and ultraviolet-A (UVA) collagen cross-linking (C3R) has shown potential to improve the signs and symptoms of bullous keratopathy .The objective of this study is to demonstrate the effects of C3R to treat bullous keratopathy.

Interventions

RADIATIONultraviolet-A

Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients with bollous keratopathy

Exclusion criteria

* corneal scarring or contemporary eye disease affecting VA were excluded.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026